News | August 12, 2021
Hester Biosciences posts PAT of Rs 11.01 cr in Q1FY22
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Shivani Satish Wagh takes on the role of Joint Managing Director
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Imaginant offers a unique measurement capability through its PELT coating thickness gauges
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Subscribe To Our Newsletter & Stay Updated
